Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2

Journal of Neuroscience

Volumn 26, Issue 2, 2006, Pages 440-447

  Smith, Patrice D ^a   Mount, Matthew P ^a   Shree, Raj ^a   Callaghan, Steve ^a   Slack, Ruth S ^a   Anisman, Hymie ^b   Vincent, Inez ^c   Wang, Xuemin ^d   Mao, Zixu ^d   Park, David S ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Cdk5; Cyclin dependent kinase 5; Dopamine; MEF2; MPTP; Myocyte enhancer factor 2; Parkinson's disease; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALPAIN; CYCLIN DEPENDENT KINASE 5; MYOCYTE ENHANCER FACTOR 2; PROTEIN P35; SERINE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWNSTREAM PROCESSING; IN VIVO STUDY; MALE; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; CALCIUM-BINDING PROTEINS; CALPAIN; CORPUS STRIATUM; CYCLIN-DEPENDENT KINASE 5; DOPAMINE; ENZYME ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MYOGENIC REGULATORY FACTORS; NERVE TISSUE PROTEINS; NEURONS; PARKINSONIAN DISORDERS; PHOSPHORYLATION; POINT MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 32544441845     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2875-05.2006     Document Type: Article

References (50)

1. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94:239-247.
2. Bu B, Li J, Davies P, Vincent I (2002) Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 22:6515-6525.
3. Carafoli E, Molinari M (1998) Calpain: a protease in search of a function? Biochem Biophys Res Commun 247:193-203.
4. Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH (1997) Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18:29-42.
5. Chan SL, Mattson MP (1999) Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 58:167-190.
6. Chergui K, Svenningsson P, Greengard P (2004) Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci USA 101:2191-2196.
7. Croall DE, McGrody KS (1994) Domain structure of calpain: mapping the binding site for calpastatin. Biochemistry 33:13223-13230.
8. Crocker SJ, Lamba WR, Smith PD, Callaghan SM, Slack RS, Anisman H, Park DS (2001) c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci USA 98:13385-13390.
9. Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborski S, Robertson GS, Anisman H, Merali Z, Park DS (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 23:4081-4091.
10. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909.
11. Franklin KB, Paxinos G (2001) The mouse brain in stereotaxic coordinates. New York: Academic.
12. Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83:731-801.
13. Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J, Mao Z (2003) Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38:33-46.
14. Hallows JL, Chen K, DePinho RA, Vincent I (2003) Decreased cyclindependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci 23:10633-10644.
15. Hayley S, Lacosta S, Merali Z, van Rooijen N, Anisman H (2001) Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: sensitization and cross-sensitization effects. Eur J Neurosci 13:1155-1165.
16. Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 24:2045-2053.
17. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469.
18. Hisanaga S, Saito T (2003) The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. NeuroSignals 12:221-229.
19. Humbert S, Dhavan R, Tsai L (2000) p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J Cell Sci 113:975-983.
20. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
21. Julien JP, Mushynski WE (1998) Neurofilaments in health and disease. Prog Nucleic Acid Res Mol Biol 61:1-23.
22. Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH (2001) p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 21:6758-6771.
23. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275:17166-17172.
24. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360-364.
25. Li BS, Zhang L, Takahashi S, Ma W, Jaffe H, Kulkarni AB, Pant HC (2002) Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J 21:324-333.
26. Li M, Linseman DA, Allen MP, Meintzer MK, Wang X, Laessig T, Wierman ME, Heidenreich KA (2001) Myocyte enhancer factor 2A and 2D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons. J Neurosci 21:6544-6552.
27. Mao Z, Wiedmann M (1999) Calcineurin enhances MEF2 DNA binding activity in calcium-dependent survival of cerebellar granule neurons. J Biol Chem 274:31102-31107.
28. Melloni E, Salamino F, Sparatore B (1992) The calpain-calpastatin system in mammalian cells: properties and possible functions. Biochimie 74:217-223.
29. Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73:979-987.
30. Moy LY, Tsai LH (2004) Cyclin-dependent kinase 5 phosphorylates serine 31 of tyrosine hydroxylase and regulates its stability. J Biol Chem 279:54487-54493.
31. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J (1997) p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl) 94:153-157.
32. Nguyen MD, Lariviere RC, Julien JP (2001) Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30:135-147.
33. Nishi A, Bibb JA, Matsuyama S, Hamada M, Higashi H, Nairn AC, Greengard P (2002) Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J Neurochem 81:832-841.
34. O'Hare MJ, Kushwaha N, Zhang Y, Aleyasin H, Callaghan SM, Slack RS, Albert PR, Vincent I, Park DS (2005) Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 25:8954-8966.
35. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB (1996) Targeted disruption of the cyclindependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 93:11173-11178.
36. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-622.
37. Pines J (1993) Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 21:921-925.
38. Ray SK, Banik NL (2003) Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr Drug Targets CNS Neurol Disord 2:173-189.
39. Rosales JL, Nodwell MJ, Johnston RN, Lee KY (2000) Cdk5/p25(nck5a) interaction with synaptic proteins in bovine brain. J Cell Biochem 78:151-159.
40. Rosales J, Han B, Lee KY (2003) Cdk7 functions as a cdk5 activating kinase in brain. Cell Physiol Biochem 13:285-296.
41. Sedarous M, Keramaris E, O'Hare M, Melloni E, Slack RS, Elce JS, Greer PA, Park DS (2003) Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 278:26031-26038.
42. Sharma P, Sharma M, Amin ND, Albers RW, Pant HC (1999) Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc Natl Acad Sci USA 96:11156-11160.
43. Shelton SB, Johnson GV (2004) Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem 88:1313-1326.
44. Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, Mount MP, O'Hare MJ, Callaghan S, Slack RS, Przedborski S, Anisman H, Park DS (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 100:13650-13655.
45. Smith PD, O'Hare MJ, Park DS (2004) CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol Med 10:445-451.
46. Tang X, Wang X, Gong X, Tong M, Park D, Xia Z, Mao Z (2005) Cyclindependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J Neurosci 25:4823-4834.
47. Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048.
48. Trimmer PA, Smith TS, Jung AB, Bennett Jr JP (1996) Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5:233-239.
49. Tsai LH, Takahashi T, Caviness Jr VS, Harlow E (1993) Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119:1029-1040.
50. Tsai LH, Delalle I, Caviness Jr VS, Chae T, Harlow E (1994) p35 is a neuralspecific regulatory subunit of cyclin-dependent kinase 5. Nature 371:419-423.